These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
231 related items for PubMed ID: 12412207
1. Thalidomide: focus on its employment in rheumatologic diseases. Ossandon A, Cassarà EA, Priori R, Valesini G. Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207 [Abstract] [Full Text] [Related]
2. [Thalidomide--a new prospective therapy in rheumatology and transplantation]. Pałgan K, Pałgan I, Dziedziczko A. Wiad Lek; 2003; 56(11-12):574-6. PubMed ID: 15058168 [Abstract] [Full Text] [Related]
3. [Thalidomide in treatment of connective diseases and vasculities]. Maruotti N, Cantatore FP, Ribatti D. Reumatismo; 2006; 58(3):187-90. PubMed ID: 17013434 [Abstract] [Full Text] [Related]
5. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. Clin Exp Rheumatol; 2015 Feb; 33(6 Suppl 94):S129-37. PubMed ID: 26486925 [Abstract] [Full Text] [Related]
6. Thalidomide: current and potential clinical applications. Calabrese L, Fleischer AB. Am J Med; 2000 Apr 15; 108(6):487-95. PubMed ID: 10781782 [Abstract] [Full Text] [Related]
7. [Thalidomide: the revival]. Grosbois B, Duguet C. Rev Med Interne; 2001 Jan 15; 22(1):5-7. PubMed ID: 11218298 [No Abstract] [Full Text] [Related]
8. Thalidomide: rationale for renewed use in immunological disorders. Schuler U, Ehninger G. Drug Saf; 1995 Jun 15; 12(6):364-9. PubMed ID: 8527011 [Abstract] [Full Text] [Related]
9. [Thalidomide and thrombosis: three observations]. Pouaha J, Martin S, Trechot P, Truchetet F, Barbaud A, Schmutz JL. Presse Med; 2001 Jun 09; 30(20):1008-9. PubMed ID: 11433688 [No Abstract] [Full Text] [Related]
10. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Walchner M, Meurer M, Plewig G, Messer G. Int J Dermatol; 2000 May 09; 39(5):383-8. PubMed ID: 10849134 [Abstract] [Full Text] [Related]
11. Thalidomide: a review of approved and investigational uses. Matthews SJ, McCoy C. Clin Ther; 2003 Feb 09; 25(2):342-95. PubMed ID: 12749503 [Abstract] [Full Text] [Related]
12. Review of thalidomide use in the pediatric population. Yang CS, Kim C, Antaya RJ. J Am Acad Dermatol; 2015 Apr 09; 72(4):703-11. PubMed ID: 25617013 [Abstract] [Full Text] [Related]
13. [Weight gain during treatment with thalidomide: a case report]. Comte H, Béné J, Auffret M, Gautier S, Salle-Staumont D. Therapie; 2014 Apr 09; 69(5):457-9. PubMed ID: 25285366 [Abstract] [Full Text] [Related]
14. [Cyclosporin for the treatment of systemic autoimmune diseases]. Tanaka Y. Nihon Rinsho; 2005 May 09; 63 Suppl 5():240-6. PubMed ID: 15954356 [No Abstract] [Full Text] [Related]
15. [Corticosteroid therapy of various systemic diseases (non-neoplastic, noninfectious)]. Sternon J, Decaux G, Nève P. Rev Med Brux; 1991 May 09; 12(5):179-85. PubMed ID: 2057665 [Abstract] [Full Text] [Related]
16. Thalidomide responsiveness in an infant with Behçet's syndrome. Shek LP, Lee YS, Lee BW, Lehman TJ. Pediatrics; 1999 Jun 09; 103(6 Pt 1):1295-7. PubMed ID: 10353947 [Abstract] [Full Text] [Related]